Cellectar Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. 

CEO
James V. Caruso
CEOJames V. Caruso
Employees
11
Employees11
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
1996
Founded1996
Employees
11
Employees11

CLRB Key Statistics

Market cap
13.67M
Market cap13.67M
Price-Earnings ratio
-0.31
Price-Earnings ratio-0.31
Dividend yield
Dividend yield
Average volume
73.70K
Average volume73.70K
High today
$3.44
High today$3.44
Low today
$3.14
Low today$3.14
Open price
$3.25
Open price$3.25
Volume
47.66K
Volume47.66K
52 Week high
$20.59
52 Week high$20.59
52 Week low
$2.45
52 Week low$2.45

Stock Snapshot

Cellectar Biosciences(CLRB) stock is priced at $3.20, giving the company a market capitalization of 13.67M. It carries a P/E multiple of -0.31.

On 2026-03-14, Cellectar Biosciences(CLRB) stock traded between a low of $3.14 and a high of $3.44. Shares are currently priced at $3.20, which is +1.8% above the low and -7.0% below the high.

The Cellectar Biosciences(CLRB)'s current trading volume is 47.66K, compared to an average daily volume of 73.7K.

During the past year, Cellectar Biosciences(CLRB) stock moved between $2.45 at its lowest and $20.59 at its peak.

During the past year, Cellectar Biosciences(CLRB) stock moved between $2.45 at its lowest and $20.59 at its peak.

CLRB News

TipRanks 5d
Cellectar Biosciences upgraded to Buy from Hold at Maxim

Maxim upgraded Cellectar Biosciences (CLRB) to Buy from Hold with a $10 price target Published first on TheFly – the ultimate source for real-time, market-movi...

TipRanks 5d
Cellectar Biosciences Charts Risky Path to Approvals

Cellectar Biosciences Inc ((CLRB)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fund-...

People also own

Based on the portfolios of people who own CLRB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.